The technological and innovative core of the Company is
its platform technology found in
its U. S. and international patents. This is a unique method of drug delivery that is highly effective in treating
women's diseases and disorders that are amenable to a local or regional approach, including
pelvic disease, breast disease and reproductive system diseases and disorders. The invention covers methods of use and formulations of drugs. The benefit of this invention is that an effective amount of drugs may be administered in
a very small volume directly to a targeted area of disease or disorder. The drug classes covered include a broad spectrum of those that are used in the treatment of women's diseases and disorders of the female pelvic and reproductive organs.
PARDEL™ (Pelvic and Reproductive Delivery) is one of the Company's patented platform technologies. PARDEL™ delivers the drug directly to the pelvic and reproductive areas, with preferred absorption and migration into the affected areas.
For drugs given locally to treat pelvic disease and reproductive system diseases and disorders, such a delivery system
may result in a reduction of side effects by lowering the dose and bypassing significant systemic circulatory levels.
Like PARDEL™, DERMODEL™ is targeted to a specific region of disease or disorder; in this case, a dermal delivery to a specific region of
the body. It does not require patches or special devices to allow drugs to penetrate the
skin and reach the areas of disease or disorder. The
DERMODEL™ technology will provide local delivery of a pharmaceutically acceptable agent without
many of the associated side effects seen by other transdermally delivered products.